Jzaneen Lalani Joins CureMark As Chief Operating Officer

RYE, N.Y., Oct. 14, 2015 /PRNewswire/ -- Curemark, a drug research and development company focused on the treatment of neurological diseases for unmet medical needs, announced today the appointment of Jzaneen Lalani as Chief Operating Officer.

"As we move toward completing our ongoing Phase III clinical trial of CM-AT in autism, and commence clinical trials with our other drug candidates, Curemark is poised for tremendous growth over the next 12 months," states Dr. Joan Fallon, founder and CEO of Curemark. "Jzaneen's legal and operational expertise will make her a powerful contributor and a valuable asset to the Curemark team as we move forward."

Lalani brings more than 15 years of experience to her role as COO that spans operational areas, including M&A, human resources and corporate communications, in biotech and healthcare, with both private and publicly traded companies. Most recently, she was the Chief Corporate Counsel of HMS Holdings Corp. Before that she served as the General Counsel of Memory Pharmaceuticals Corp. Lalani holds a law degree from the University of Victoria, Canada and a Masters of Law and International Affairs from Columbia University.

About Curemark, LLC

Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark's pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson's disease. For additional information, please visit our website at http://www.curemark.com or follow @curemark on Twitter.

Logo - http://photos.prnewswire.com/prnh/20150922/269120LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jzaneen-lalani-joins-curemark-as-chief-operating-officer-300159577.html

SOURCE Curemark

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i